Overview
Enveda Biosciences uses machine learning, metabolomics, and robotics to explore the largely untapped natural world for drug discovery. Its main asset is a proprietary high-throughput platform that runs many experiments to generate a comprehensive dataset of small molecules, including their chemical structures, biological activity, and how they distribute in organs. This data helps identify potential drug leads quickly and supports partnerships with healthcare and pharmaceutical companies through collaborations and licensing of discoveries. Unlike many rivals, Enveda focuses on expanding knowledge of natural product chemistry beyond the small portion already known, aiming to accelerate the pace of drug discovery by systematically exploring natural chemical space and building a pipeline for its partners.
Work here?Claim your company
Simplify's take
What believers are saying
- September 2026 financing totaled $461 million, lifting Enveda to a $2 billion valuation.
- ENV-294 showed positive Phase 1b data in March and late-breaker EADV presentation September 2026.
- ENV-308 reported positive Phase 1 results in August 2026, enabling obesity expansion.
What critics are saying
- No approved Enveda drug exists; every value driver still depends on unproven Phase 1b readouts.
- ENV-294 and ENV-308 face crowded markets from Dupixent, GLP-1s, and topical biologics by 2027.
- If ENV-6946 fails in IBD, Enveda's clinical story collapses before 2028.
What makes Enveda unique
- Enveda's PRISM converts natural-product chemistry into candidates faster than conventional discovery.
- Anthropic collaboration drafted IND modules in four hours, not three months, in October 2026.
- By September 2026, Enveda had 17 drug candidates and three clinical programs.
Help us improve and share your feedback! Did you find this helpful?